CGH
EW icon

Crossmark Global Holdings’s Edwards Lifesciences EW Stock Holding History

Crossmark Global Holdings’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.34M Buy
36,938
+345
+0.9% +$28.9K 0.04% 332
2026
Q1 		$2.93M Sell
36,593
-517
-1% -$42.6K 0.04% 348
2025
Q4 		$3.16M Buy
37,110
+3,978
+12% +$326K 0.05% 332
2025
Q3 		$2.58M Sell
33,132
-58
-0.2% -$4.53K 0.04% 376
2025
Q2 		$2.6M Sell
33,190
-1,312
-4% -$97.8K 0.04% 364
2025
Q1 		$2.5M Sell
34,502
-232
-0.7% -$16.6K 0.04% 362
2024
Q4 		$2.57M Sell
34,734
-101
-0.3% -$7.07K 0.05% 338
2024
Q3 		$2.3M Sell
34,835
-6,617
-16% -$481K 0.04% 380
2024
Q2 		$3.83M Sell
41,452
-83
-0.2% -$7.35K 0.07% 275
2024
Q1 		$3.97M Sell
41,535
-3,245
-7% -$273K 0.08% 269
2023
Q4 		$3.42M Sell
44,780
-3,495
-7% -$243K 0.07% 287
2023
Q3 		$3.52M Buy
48,275
+511
+1% +$41.1K 0.08% 271
2023
Q2 		$4M Sell
47,764
-709
-1% -$61.6K 0.09% 255
2023
Q1 		$4.01M Sell
48,473
-1,430
-3% -$112K 0.09% 240
2022
Q4 		$3.72M Buy
49,903
+4,205
+9% +$324K 0.09% 245
2022
Q3 		$3.78M Sell
45,698
-309
-0.7% -$29.7K 0.1% 221
2022
Q2 		$4.37M Sell
46,007
-17,594
-28% -$1.82M 0.11% 209
2022
Q1 		$7.49M Buy
63,601
+163
+0.3% +$18.3K 0.17% 158
2021
Q4 		$8.22M Sell
63,438
-1,153
-2% -$134K 0.18% 143
2021
Q3 		$7.31M Sell
64,591
-7,694
-11% -$878K 0.17% 145
2021
Q2 		$7.49M Sell
72,285
-1,551
-2% -$146K 0.18% 141
2021
Q1 		$6.18M Sell
73,836
-873
-1% -$73.8K 0.15% 160
2020
Q4 		$6.82M Sell
74,709
-9,230
-11% -$766K 0.17% 139
2020
Q3 		$6.7M Buy
83,939
+217
+0.3% +$16.9K 0.19% 138
2020
Q2 		$5.79M Buy
83,722
+4,741
+6% +$337K 0.17% 143
2020
Q1 		$4.97M Buy
78,981
+4,161
+6% +$300K 0.18% 142
2019
Q4 		$5.82M Sell
74,820
-2,754
-4% -$215K 0.16% 153
2019
Q3 		$5.69M Buy
77,574
+20,955
+37% +$1.47M 0.17% 153
2019
Q2 		$3.49M Sell
56,619
-1,779
-3% -$108K 0.1% 240
2019
Q1 		$3.72M Sell
58,398
-1,770
-3% -$101K 0.11% 225
2018
Q4 		$3.07M Sell
60,168
-6,657
-10% -$337K 0.1% 249
2018
Q3 		$3.88M Sell
66,825
-4,191
-6% -$205K 0.1% 248
2018
Q2 		$3.45M Sell
71,016
-1,830
-3% -$85.4K 0.09% 252
2018
Q1 		$3.39M Sell
72,846
-3,720
-5% -$162K 0.09% 280
2017
Q4 		$2.88M Buy
76,566
+6,795
+10% +$249K 0.07% 333
2017
Q3 		$2.54M Buy
+69,771
New +$2.66M 0.07% 352
2016
Q3 		$2.54M Buy
+69,771
New +$2.63M 0.07% 352

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
FFM
Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
NO
Ninety One Cape Town, South Africa $1.85B AUM 62.46% 1-Year Est. Return

Crossmark Global Holdings's EW Position: Q2 2026 in Review

Crossmark Global Holdings increased its Edwards Lifesciences (EW) stake by 0.94% in Q2 2026, buying an estimated $28.9K and bringing the position to 36,938 shares worth $3.34M. The position accounts for 0.04% of the portfolio, ranked #332.

Crossmark Global Holdings first reported a position in EW in Q3 2016 and has held it in 37 quarters since. The position peaked at $8.22M in Q4 2021. 195 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Crossmark Global Holdings held 36,938 shares of Edwards Lifesciences worth $3.34M as of Q2 2026.
  • Crossmark Global Holdings bought 345 Edwards Lifesciences shares in Q2 2026, an estimated $28.9K.
  • Edwards Lifesciences made up 0.04% of Crossmark Global Holdings's portfolio in Q2 2026, its #332 holding.
  • Crossmark Global Holdings first reported a position in Edwards Lifesciences in Q3 2016 and has held it in 37 quarters since.
  • Crossmark Global Holdings's Edwards Lifesciences position peaked at $8.22M in Q4 2021.
  • 195 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.